What is BMY's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 127.71B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BMY?

P/E (TTM) is 13.49 and 52-week range is $42.52 to $68.64 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BMY figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BMY?

The company profile lists revenue (TTM) near $49.09B, net income (TTM) near $9.26B, EPS (TTM) near $4.54 when available from the market-data feed. Figures are informational and may lag live markets.

Does BMY show a dividend on Chartloom?

The overview lists dividend per share (TTM) near $7.33, yield near 6.06%, ex-dividend date Oct 2, 2026 when those figures are present. Dividend history is compiled from vendor data, not a distribution notice.

Where is Bristol-Myers Squibb Company based, and what identifiers does Chartloom list?

The company context section lists headquarters in Princeton, New Jersey, US, 2.04B shares outstanding, ISIN US1101221083 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Bristol-Myers Squibb Company

$BMY

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).

Employees

32,500

Website

www.bms.com

IPO

1980-03-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NEW YORK STOCK EXCHANGE, INC.

ISIN

US1101221083

Headquarters

Princeton, New Jersey, US

Shares outstanding

2.04B

NAICS sector

Manufacturing

Institutional ownership

84.98%

Browse other companiesFree AI scores and summaries for more stocks